Vocabria is a drug owned by Viiv Healthcare Co. It is protected by 2 US drug patents filed in 2021 out of which none have expired yet. Vocabria's patents have been open to challenges since 21 January, 2025. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2026. Details of Vocabria's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8410103 | (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent |
Apr, 2026
(9 months from now) | Active |
| US10927129 | N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity |
Apr, 2026
(9 months from now) | Active |
FDA has granted several exclusivities to Vocabria. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vocabria, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vocabria.
Exclusivity Information
Vocabria holds 3 exclusivities out of which 2 have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Vocabria's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-273) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Several oppositions have been filed on Vocabria's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Vocabria's generic, the next section provides detailed information on ongoing and past EP oppositions related to Vocabria patents.
Vocabria's Oppositions Filed in EPO
Vocabria has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 28, 2014, by Ahrens, Gabriele. This opposition was filed on patent number EP06758843A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17195280A | Feb, 2020 | Gilead Sciences, Inc. | Opposition rejected |
| EP16154531A | Dec, 2018 | Gilead Sciences, Inc. | Patent maintained as amended |
| EP06822311A | Nov, 2016 | Zwicker Schnappauf & Partner PartG mbB | Opposition procedure closed |
| EP06758843A | May, 2014 | Ahrens, Gabriele | Opposition procedure closed |
US patents provide insights into the exclusivity only within the United States, but Vocabria is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vocabria's family patents as well as insights into ongoing legal events on those patents.
Vocabria's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vocabria's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 28, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vocabria Generics:
There are no approved generic versions for Vocabria as of now.
Alternative Brands for Vocabria
Vocabria which is used for treating HIV-1 infection in adults and adolescents over 12 years old with a weight of at least 35 kg., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Viiv Hlthcare |
| |||
About Vocabria
Vocabria is a drug owned by Viiv Healthcare Co. It is used for treating HIV-1 infection in adults and adolescents over 12 years old with a weight of at least 35 kg. Vocabria uses Cabotegravir Sodium as an active ingredient. Vocabria was launched by Viiv Hlthcare in 2021.
Approval Date:
Vocabria was approved by FDA for market use on 21 January, 2021.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Vocabria is 21 January, 2021, its NCE-1 date is estimated to be 21 January, 2025.
Active Ingredient:
Vocabria uses Cabotegravir Sodium as the active ingredient. Check out other Drugs and Companies using Cabotegravir Sodium ingredient
Treatment:
Vocabria is used for treating HIV-1 infection in adults and adolescents over 12 years old with a weight of at least 35 kg.
Dosage:
Vocabria is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 30MG BASE | TABLET | Prescription | ORAL |